Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948434 | 0.98 | ALDH1A1 (0.32) | MAPTNPSR1KDM4EMCOLN3SMN1; SMN2 | |
| SCHEMBL170248 | 0.92 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1CYP2A13HPGD | |
| SCHEMBL10891279 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL2229452 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL3658217 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL286072 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL2569149 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL4712511 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL6050828 | 0.83 | CYP2D6 (0.32) | KMT2A | |
| SCHEMBL285243 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4815429-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| EP-1723203-B1 | VIOLET COLORANT FOR COLOUR FILTERS, INKS FOR INK-JET, ELECTROPHOTOGRAPHIC TONERS AND DEVELOPERS AND E-INKS | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2011-04-20 | — | — | EP | claimed |
| EP-1723203-A1 | VIOLET COLORANT FOR COLOUR FILTERS, INKS FOR INK-JET, ELECTROPHOTOGRAPHIC TONERS AND DEVELOPERS AND E-INKS | Clariant Produkte (Deutschland) GmbH (DE) | 2006-11-22 | — | — | EP | claimed |
| WO-2005085367-A1 | VIOLET COLORANT FOR COLOUR FILTERS, INKS FOR INK-JET, ELECTROPHOTOGRAPHIC TONERS AND DEVELOPERS AND E-INKS | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2005-09-15 | — | — | WO | claimed |
| EP-1163239-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | claimed |
| WO-2000055154-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | claimed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1163239-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055154-A1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | PTGIS, PTGIR, FPR1 | MAPT 4189/4885NPSR1 1184/4885KDM4E 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.